2024-10-26 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis

**Company Overview:** AbbVie Inc. is a global biopharmaceutical company focused on developing and marketing innovative therapies for various diseases.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** ABBV (146.5) outperformed VOO (135.48) by 11.02%. 
* **Relative Outperformance:** This places ABBV in the 52.99th percentile of historical outperformance compared to VOO, indicating a moderately strong relative performance.

**2. Recent Price Action:**

* **Closing Price:** 189.65 (Last Market: 187.82)
* **Moving Averages:** 
    * 5-Day: 188.34
    * 20-Day: 192.7
    * 60-Day: 193.26
* **Analysis:** The stock is currently trading below all three moving averages, indicating potential downward pressure. 

**3. Technical Indicators:**

* **RSI:** 38.16 (Below 50), indicating a potentially oversold condition.
* **PPO:** -0.32 (Negative), indicating a bearish trend.
* **Delta_Previous_Relative_Divergence:** -4.46 (-), suggests a recent short-term downward trend.
* **Expected Return:** 3.06%, indicating a potential long-term (2+ years) outperformance compared to the S&P 500 for a buy-and-hold strategy.

**4. Recent Earnings & Outlook:**

| Date | EPS | Expected EPS | 
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Analysis:** ABBV has consistently beaten earnings estimates in the past, suggesting a strong underlying business performance. The most recent earnings (2024-07-25) showed a beat of $0.08 per share, further reinforcing positive sentiment.

**5. News and Recent Events:**

* **Earnings Announcement:** As of today, there haven't been any recent earnings announcements within the past two days.
* **Market Outlook:** While AbbVie's pipeline is strong, the upcoming patent expirations for key drugs like Humira are a significant concern. However, the company is aggressively exploring alternative therapies and expanding its portfolio to mitigate the risk.
* **Analyst Opinions:** The majority of analysts maintain a "buy" or "hold" rating on ABBV, citing the company's strong track record, growing pipeline, and attractive dividend yield.
* **Performance Highlights:** Despite facing challenges, ABBV has consistently delivered strong financial performance, making it an attractive investment option for long-term investors.

**6. Overall Analysis:**

ABBV has shown strong performance in recent years, consistently outperforming the market. While the stock is currently facing some downward pressure, the company's strong earnings track record, robust pipeline, and attractive dividend yield suggest a potentially good long-term investment opportunity. The stock is currently trading at a discount to its moving averages and may offer a potential entry point for investors seeking a long-term investment with an attractive risk-reward profile.

**7. Final Thoughts:**

AbbVie is a well-established and profitable company with a strong track record of growth and a consistent dividend yield. While the upcoming patent expiration of Humira is a notable risk, AbbVie is actively mitigating this challenge through its diverse pipeline and strategic initiatives. Investors seeking long-term exposure to the healthcare sector may consider ABBV for its potential growth and value.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Investing in the stock market involves risks and potential for loss. Always conduct thorough research and consult with a financial advisor before making any investment decisions. 
